Femasys Expands Fertility Portfolio into UNC Health System
Event summary
- Femasys partners with UNC Health to introduce its FemaSeed® fertility portfolio across OB/GYN care locations statewide.
- FemVue® fertility evaluation and FemaSeed® are now available as first-line treatment options within UNC Health’s OB/GYN practices.
- The partnership aims to expand access to fertility care, reducing barriers such as distance and cost for patients.
- Femasys’ fertility portfolio includes diagnostic tools like FemVue and SpermVue, along with FemaSeed Complete for in-office treatments.
The big picture
Femasys’ partnership with UNC Health marks a strategic shift toward earlier fertility care within OB/GYN practices, addressing accessibility and cost barriers. This move aligns with broader industry trends of integrating specialized fertility services into primary care settings, potentially reducing the need for referrals to infertility specialists. The collaboration also highlights the growing emphasis on community-based healthcare delivery, combining local access with academic expertise.
What we're watching
- Market Expansion
- How Femasys will leverage this partnership to expand its fertility portfolio into additional academic health systems.
- Regulatory Progress
- Whether Femasys can sustain momentum in advancing FemBloc toward U.S. FDA approval.
- Operational Integration
- The pace at which UNC Health integrates Femasys’ fertility technologies into its existing OB/GYN practices.
Related topics